• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

雄激素剥夺疗法与后续角膜炎风险

Androgen deprivation therapy and the risk of subsequent keratitis.

作者信息

Liu Dai-Wei, Hsu Ren-Jun, Huang Sheng-Yao, Liao Yen-Hsiang, Wu Chen-Ta, Hsu Wen-Lin

机构信息

Department of Radiation Oncology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan.

School of Medicine, Tzu Chi University, Hualien, Taiwan.

出版信息

Tzu Chi Med J. 2020 Dec 4;33(1):55-60. doi: 10.4103/tcmj.tcmj_31_20. eCollection 2021 Jan-Mar.

DOI:10.4103/tcmj.tcmj_31_20
PMID:33505879
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7821820/
Abstract

OBJECTIVES

The objective of the study was to determine the risk of subsequent keratitis in prostate cancer (PCa) patients treated with androgen deprivation therapy (ADT).

MATERIALS AND METHODS

Three thousand three hundred and nine patients with PCa were identified using data from Taiwan's National Health Insurance Research Database for 2001 through 2013. Among those patients, 856 treated with ADT comprised the study group, while 856 non-ADT-treated patients matched with 1:1 propensity-score-matched analysis comprised the control group. The demographic characteristics and comorbidities of all the patients were analyzed, and Cox proportional hazards regression was utilized to determine the hazard ratios (HRs) for subsequent keratitis.

RESULTS

A total of 157 (9.2%) patients had newly diagnosed keratitis. Compared to the non-ADT-treated patients, the ADT-treated patients had a reduced risk of subsequent keratitis, with an adjusted HR of 0.38 (95% confidence interval: 0.27-0.55; < 0.001).

CONCLUSION

ADT treatment apparently decreased the risk of subsequent keratitis in the investigated PCa patients, but the clinical significance of this finding should be further assessed in additional studies.

摘要

目的

本研究的目的是确定接受雄激素剥夺疗法(ADT)治疗的前列腺癌(PCa)患者发生继发性角膜炎的风险。

材料与方法

利用台湾国民健康保险研究数据库2001年至2013年的数据,确定了3309例PCa患者。其中,856例接受ADT治疗的患者组成研究组,856例未接受ADT治疗的患者通过1:1倾向评分匹配分析组成对照组。分析了所有患者的人口统计学特征和合并症,并采用Cox比例风险回归分析来确定继发性角膜炎的风险比(HRs)。

结果

共有157例(9.2%)患者新诊断为角膜炎。与未接受ADT治疗的患者相比,接受ADT治疗的患者发生继发性角膜炎的风险降低,校正后的HR为0.38(95%置信区间:0.27-0.55;P<0.001)。

结论

ADT治疗明显降低了所研究的PCa患者发生继发性角膜炎的风险,但这一发现的临床意义应在更多研究中进一步评估。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f18a/7821820/b9dd8d530ff3/TCMJ-33-55-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f18a/7821820/6cea96aa1ed5/TCMJ-33-55-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f18a/7821820/b9dd8d530ff3/TCMJ-33-55-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f18a/7821820/6cea96aa1ed5/TCMJ-33-55-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f18a/7821820/b9dd8d530ff3/TCMJ-33-55-g002.jpg

相似文献

1
Androgen deprivation therapy and the risk of subsequent keratitis.雄激素剥夺疗法与后续角膜炎风险
Tzu Chi Med J. 2020 Dec 4;33(1):55-60. doi: 10.4103/tcmj.tcmj_31_20. eCollection 2021 Jan-Mar.
2
No increased risk of psoriasis in patients receiving androgen deprivation therapy for prostate cancer: a 17-year population-based study.接受雄激素剥夺疗法治疗前列腺癌的患者患银屑病风险未增加:一项基于人群的17年研究
Ther Clin Risk Manag. 2018 Sep 28;14:1831-1837. doi: 10.2147/TCRM.S175244. eCollection 2018.
3
Androgen deprivation therapy and the risk of tenosynovitis in prostate cancer patients.雄激素剥夺疗法与前列腺癌患者肌腱炎风险。
Int Urol Nephrol. 2019 Jul;51(7):1113-1119. doi: 10.1007/s11255-019-02152-y. Epub 2019 May 20.
4
Decreased Risk of Renal Calculi in Patients Receiving Androgen Deprivation Therapy for Prostate Cancer.接受雄激素剥夺疗法治疗前列腺癌的患者肾结石风险降低。
Int J Environ Res Public Health. 2020 Mar 9;17(5):1762. doi: 10.3390/ijerph17051762.
5
Androgen deprivation therapy for prostate cancer and the risk of thyroid diseases.前列腺癌的雄激素剥夺治疗与甲状腺疾病风险
Prostate. 2022 May;82(7):809-815. doi: 10.1002/pros.24323. Epub 2022 Feb 28.
6
Association between Androgen Deprivation Therapy and Risk of Dementia in Men with Prostate Cancer.雄激素剥夺疗法与前列腺癌男性患痴呆症风险之间的关联。
Cancers (Basel). 2021 Jul 31;13(15):3861. doi: 10.3390/cancers13153861.
7
Androgen deprivation therapy for prostate cancer and the risk of autoimmune diseases.雄激素剥夺疗法治疗前列腺癌与自身免疫性疾病风险。
Prostate Cancer Prostatic Dis. 2019 Sep;22(3):475-482. doi: 10.1038/s41391-019-0130-9. Epub 2019 Jan 28.
8
Risks of Major Long-Term Side Effects Associated with Androgen-Deprivation Therapy in Men with Prostate Cancer.前列腺癌男性雄激素剥夺治疗相关的主要长期副作用风险。
Pharmacotherapy. 2018 Oct;38(10):999-1009. doi: 10.1002/phar.2168. Epub 2018 Sep 4.
9
Is androgen deprivation therapy associated with cerebral infarction in patients with prostate cancer? A Korean nationwide population-based propensity score matching study.雄激素剥夺疗法是否与前列腺癌患者的脑梗死相关?一项基于韩国全国人群的倾向评分匹配研究。
Cancer Med. 2019 Aug;8(9):4475-4483. doi: 10.1002/cam4.2325. Epub 2019 Jun 10.
10
Androgen Deprivation Therapy for Prostate Cancer Did Not Increase the Risk of Retinal Vascular Occlusion: A Population-Based Cohort Study.雄激素剥夺疗法(ADT)不会增加前列腺癌患者视网膜血管闭塞的风险:一项基于人群的队列研究。
Int J Environ Res Public Health. 2022 Feb 17;19(4):2268. doi: 10.3390/ijerph19042268.

本文引用的文献

1
Androgen deprivation therapy for prostate cancer and the risk of autoimmune diseases.雄激素剥夺疗法治疗前列腺癌与自身免疫性疾病风险。
Prostate Cancer Prostatic Dis. 2019 Sep;22(3):475-482. doi: 10.1038/s41391-019-0130-9. Epub 2019 Jan 28.
2
Immune Modulation by Androgen Deprivation and Radiation Therapy: Implications for Prostate Cancer Immunotherapy.雄激素剥夺和放射治疗的免疫调节:对前列腺癌免疫治疗的意义
Cancers (Basel). 2017 Jan 27;9(2):13. doi: 10.3390/cancers9020013.
3
Cancer Statistics, 2017.《2017 年癌症统计》
CA Cancer J Clin. 2017 Jan;67(1):7-30. doi: 10.3322/caac.21387. Epub 2017 Jan 5.
4
Androgen deprivation increases the risk of fracture in prostate cancer patients: a population-based study in Chinese patients.雄激素剥夺增加前列腺癌患者骨折风险:一项基于中国患者人群的研究。
Osteoporos Int. 2015 Sep;26(9):2281-90. doi: 10.1007/s00198-015-3135-9. Epub 2015 May 20.
5
Do androgen deprivation drugs affect the immune cross-talk between mononuclear and prostate cancer cells?雄激素剥夺药物是否会影响单核细胞和前列腺癌细胞之间的免疫相互作用?
Biomed Pharmacother. 2014 Feb;68(1):21-4. doi: 10.1016/j.biopha.2013.12.007. Epub 2013 Dec 24.
6
Cardiovascular and metabolic complications during androgen deprivation: exercise as a potential countermeasure.雄激素剥夺治疗期间的心血管和代谢并发症:运动作为一种潜在的应对措施。
Prostate Cancer Prostatic Dis. 2009;12(3):233-40. doi: 10.1038/pcan.2009.12. Epub 2009 Jun 2.
7
Effect of luteinizing hormone-releasing hormone (LHRH) analogue treatment on a cytokine profile in prostate cancer patients.促黄体生成素释放激素(LHRH)类似物治疗对前列腺癌患者细胞因子谱的影响。
Pharmacol Rep. 2008 May-Jun;60(3):399-403.
8
Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis.前列腺癌中的雄激素剥夺疗法与动脉粥样硬化的代谢风险
J Clin Endocrinol Metab. 2008 Jun;93(6):2042-9. doi: 10.1210/jc.2007-2595. Epub 2008 Mar 18.
9
Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer.雄激素剥夺疗法对免疫系统的影响:对前列腺癌联合治疗的启示。
Front Biosci. 2007 Sep 1;12:4957-71. doi: 10.2741/2441.
10
Androgen control of gene expression in the mouse meibomian gland.雄激素对小鼠睑板腺基因表达的调控
Invest Ophthalmol Vis Sci. 2005 Oct;46(10):3666-75. doi: 10.1167/iovs.05-0426.